ライフサイエンスコーパス: lymph node dissection

1 may require chemotherapy, radiotherapy, and lymph node dissection.

2 all survival for those treated with axillary lymph node dissection.

3 ity and better quality of life than axillary lymph node dissection.

4 ts initially managed without retroperitoneal lymph node dissection.

5 xamined receipt of radiotherapy and axillary lymph node dissection.

6 e what should be considered the standard for lymph node dissection.

7 those treated with radical hysterectomy and lymph node dissection.

8 l nodes (SNs) were considered for completion lymph node dissection.

9 nt metastasis and with documentation of full lymph node dissection.

10 n enjoy significant long-term survival after lymph node dissection.

11 isplatin) plus radical cystectomy and pelvic lymph node dissection.

12 that reported in previous series of elective lymph node dissection.

13 All patients were offered axillary lymph node dissection.

14 he initial group went on to undergo axillary lymph node dissection.

15 axillary nodal involvement remains complete lymph node dissection.

16 cessary complications of a complete axillary lymph node dissection.

17 d have been spared the morbidity of axillary lymph node dissection.

18 1987 and underwent radical prostatectomy and lymph node dissection.

19 size continue to mandate completion axillary lymph node dissection.

20 urate, less invasive alternative to axillary lymph node dissection.

21 al excision, sentinel lymph node biopsy, and lymph node dissection.

22 ll patients had breast surgery with axillary lymph node dissection.

23 entinel lymph node biopsy (SLNB) or axillary lymph node dissection.

24 lgrastim followed by radical cystectomy with lymph node dissection.

25 will determine the true benefit of extended lymph node dissection.

26 lanoma who subsequently underwent completion lymph node dissection.

27 ated biochemical cure rates after systematic lymph node dissection.

28 e, adjuvant chemotherapy, or retroperitoneal lymph-node dissection.

29 omised trials of adjuvant radiotherapy after lymph-node dissection.

30 y a ureteral injury incurred during sentinel-lymph-node dissection.

31 imaging decreases the number of unnecessary lymph node dissections.

32 years) with breast cancer before 52 axillary lymph node dissections.

33 imately 10% of women do not have an axillary lymph node dissection, 11% to 26% do not have their horm

34 Of the 9 patients who underwent lymph node dissection, 4 (44%) had residual nodal diseas

35 or-positive SNs, 11 (78%) underwent complete lymph node dissection; 4 had tumor-positive non-SNs.

36 risk, 0.83 [CI, 0.77 to 0.90]) and axillary lymph node dissection (adjusted relative risk, 0.81 [CI,

37 east cancer, the role of completion axillary lymph node dissection (ALND) after identification of nod

38 Axillary lymph node dissection (ALND) as part of surgical treatme

39 SLNB has replaced axillary lymph node dissection (ALND) as the staging modality of

40 nformation with less morbidity than axillary lymph node dissection (ALND) for patients with clinicall

41 psy (SLNB) was developed to replace axillary lymph node dissection (ALND) for staging early breast ca

42 Axillary lymph node dissection (ALND) has been a part of breast c

43 Axillary lymph node dissection (ALND) has been a standard procedu

44 des (SLNs) were negative, SLNB with axillary lymph node dissection (ALND) if SLNB or PET was positive

45 st cancer patients, the role of the axillary lymph node dissection (ALND) in the management of clinic

46 Recent enthusiasm for limiting axillary lymph node dissection (ALND) in women with breast cancer

47 ode dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to that of w

48 ACOSOG Z0011 established that axillary lymph node dissection (ALND) is unnecessary in patients

49 ntinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) may be because of unrecogni

50 or macrometastasis (Ma), leading to axillary lymph node dissection (ALND) only when strictly necessar

51 sted of either total mastectomy and axillary lymph node dissection (ALND) or segmental mastectomy and

52 h nodes (SLNs) randomized either to axillary lymph node dissection (ALND) or sentinel lymph node diss

53 all cases with a tumor-involved SN, axillary lymph node dissection (ALND) was recommended.

54 After NAC, SLN surgery and axillary lymph node dissection (ALND) were planned.

55 ed that 20 to 30 cases of SLND with axillary lymph node dissection (ALND) would enable surgeons to id

56 rial in which SNB was compared with axillary lymph node dissection (ALND), four limited meta-analyses

57 sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or none.

58 sitive SLN who underwent completion axillary lymph node dissection (ALND).

59 (SLNs) who did and did not undergo axillary lymph node dissection (ALND).

60 ma (BCRL) in patients who underwent axillary lymph node dissection (ALND).

61 (SLN) metastases should not receive axillary lymph node dissection (ALND).

62 (SLN) metastases should not receive axillary lymph node dissection (ALND).

63 ized in 4 groups: SLN-negative with axillary lymph node dissection (ALND; n = 326), SLN-negative with

64 The goals of axillary-lymph-node dissection (ALND) are to maximise survival, p

65 still offer outcomes equivalent to axillary-lymph-node dissection (ALND).

66 sentinel lymph node biopsy [SNB] or axillary lymph node dissection [ALND]) were compared with US and

67 survival for patients treated with sentinel lymph node dissection alone was noninferior to overall s

68 Retroperitoneal lymph node dissection also appears to be worthwhile in c

69 istant disease ('desperation retroperitoneal lymph node dissection'), although the relapse rate is hi

70 s were randomly assigned to receive axillary lymph node dissection and 2404 to receive axillary radio

71 , 744 had been randomly assigned to axillary lymph node dissection and 681 to axillary radiotherapy;

72 N had additional lymph nodes in the complete lymph node dissection and 7.5% of the patients with posi

73 he roles of laparoscopic nephroureterectomy, lymph node dissection and adjuvant chemotherapy in advan

74 Radical cystectomy with an appropriate lymph node dissection and an appropriate form of urinary

75 g AFP and hCG shortly before retroperitoneal lymph node dissection and at the start of each chemother

76 Axillary lymph node dissection and axillary radiotherapy after a

77 idity traditionally associated with regional lymph node dissection and increasing survival in subgrou

78 lly curative resections consisting of portal lymph node dissection and liver parenchymal resections.

79 Lymph node dissection and postimplantation prostatic bio

80 st-conserving surgery combined with axillary lymph node dissection and radiotherapy or mastectomy are

81 Currently, the optimal boundaries of pelvic lymph node dissection and the minimum number of nodes to

82 urvival between those patients who underwent lymph node dissection and those who did not.

83 alized lymph node before completion axillary lymph node dissection and used radiography of the specim

84 e pattern could lead to unnecessary axillary lymph node dissections and lymphedema.

85 went an initial SLNB, 37.2% initial axillary lymph node dissection, and 6.3% no axillary surgery.

86 with residual disease underwent mastectomy, lymph node dissection, and radiotherapy.

87 t chemotherapy reduces the need for axillary lymph node dissection, and SLNB is an accurate method of

88 imary tumor therapy, to not receive axillary lymph node dissection, and to not receive radiation ther

89 thickness, body site, ulceration, performed lymph node dissection, and treatment.

90 opsy, but also lymph-node sampling, axillary-lymph-node dissection, and observation alone.

91 e a separate incision is needed for axillary lymph-node dissection, and postoperative radiotherapy is

92 For selected patients, axillary lymph node dissection appears to have little influence o

93 The therapeutic benefits of lymph node dissection are still controversial.

94 ic or diagnostic guidelines regarding pelvic lymph node dissection are, however, currently available.

95 ignificantly less likely to receive axillary lymph node dissection as determined by logistic regressi

96 arly breast cancer and has replaced complete lymph node dissection as the staging modality of choice

97 Process of care (ie, time to treatment, lymph node dissection), as well as outcome measures (ie,

98 Pelvic lymph node dissection at the time of radical cystectomy

99 of agreement of what constitutes an adequate lymph node dissection at the time of radical cystectomy

100 ll patients who underwent selective sentinel lymph node dissection at the UCSF Melanoma Center from 1

101 ive surgical margin rates, thorough extended lymph node dissection based on tenets of oncological pri

102 e I testis cancer has led to retroperitoneal lymph node dissection being performed mostly after chemo

103 underwent en bloc esophagectomy with radical lymph node dissection between 1988 and 1998.

104 ostatectomy and anatomically extended pelvic lymph node dissection between 1988 and 2010 at two terti

105 rature to clarify the current role of pelvic lymph node dissection both as a staging modality as well

106 We have previously found that axillary lymph node dissection, both clinically and in a mouse mo

107 (SLNs) generally undergo completion axillary lymph node dissection (cALND), either concurrently with

108 Esophagectomy with three-field lymph node dissection can be performed with a low mortal

109 initial reports suggest that an appropriate lymph node dissection can be performed.

110 Axillary lymph node dissection can identify the presence of metas

111 -lymph-node involvement, completion axillary-lymph-node dissection can be omitted or replaced by axil

112 Minimally invasive retroperitoneal lymph node dissection carries safety and oncologic equiv

113 onducted regarding SLN biopsy and completion lymph node dissection (CLND) after a positive sentinel n

114 terferon alfa-2b therapy (HDI) or completion lymph node dissection (CLND) for patients with melanoma

115 ic is whether routine 'prophylactic' central lymph node dissection (CLND) in patients without evidenc

116 Completion lymph node dissection (CLND) is recommended for all pati

117 entinel lymph node biopsy (SLNB) or complete lymph node dissection (CLND) to all patients with MCC; h

118 ch patients may most benefit from completion lymph node dissection (CLND).

119 front SLNB and reduces the need for axillary lymph node dissection compared with SLNB prior to NAC.

120 ssively less extensive, with formal axillary lymph node dissection confined to a dwindling group of p

121 Axillary lymph node dissection continues to be routinely applied

122 Retroperitoneal lymph node dissection continues to play a crucial role i

123 he body of literature suggesting an extended lymph node dissection cures more patients than lesser an

124 : What is the effect of different extents of lymph node dissection (D1, D2, and D3 lymphadenectomy) i

125 The optimum extent of lymph-node dissection (D1 vs D2) is controversial.

126 mphadenectomy (the most conservative type of lymph node dissection), D2 lymphadenectomy (but not D3)

127 for intraoperative or postoperative axillary lymph node dissection decisions.

128 Although elective lymph node dissection decreased the rate of recurrence,

129 rker molecular assay to immediate completion lymph-node dissection (dissection group) or nodal observ

130 am to determine whether elective (immediate) lymph node dissection (ELND) for intermediate-thickness

131 entinel node biopsy (SNB) to extended pelvic lymph node dissection (ePLND) remains controversial.

132 5% embryonal carcinoma, and retroperitoneal lymph node dissection for clinical stage I disease in Ja

133 eillance rather than primary retroperitoneal lymph node dissection for clinical stage I testis cancer

134 al thyroidectomy with 'therapeutic' cervical lymph node dissection for involved lymph nodes is the st

135 After lateral lymph node dissection for metastatic thyroid cancer, dys

136 nd, SLN biopsy facilitates early therapeutic lymph node dissection for those patients with nodal meta

137 ore likely to recommend prophylactic central lymph node dissection for thyroid cancer regardless of t

138 year suggest that - in high-volume centers - lymph node dissection for urologic cancers is equivalent

139 The value of completion lymph-node dissection for patients with sentinel-node me

140 viously undisputed gold standard of axillary-lymph-node dissection for staging has now been replaced

141 rred in four of 744 patients in the axillary lymph node dissection group and seven of 681 in the axil

142 In the axillary lymph node dissection group, 220 (33%) of 672 patients w

143 compared with an expected 2% in the axillary lymph node dissection group.

144 (33%) of 672 patients who underwent axillary lymph node dissection had additional positive nodes.

145 or = 1.5 mm in thickness undergoing elective lymph node dissection had histologically positive nodes

146 The role of pelvic lymph node dissection has evolved over the past 60 years

147 are accepted, an optimal template for pelvic lymph node dissection has not been established.

148 s (SLNs) are recommended to undergo axillary lymph node dissection if extranodal extension (ENE) is p

149 biopsy (followed by an immediate completion lymph node dissection if positive) provided T3 melanoma

150 ers while avoiding the morbidity of axillary lymph node dissection if the nodes do not contain cancer

151 cted to proceed with upfront RC and extended lymph node dissection in conjunction with construction o

152 m radiation, and the role of retroperitoneal lymph node dissection in disseminated nonseminomatous ca

153 evant studies on the role of retroperitoneal lymph node dissection in early and advanced stages of di

154 To reduce extensive lymph node dissection in patients and to decrease subseq

155 it is time to reassess the role of axillary lymph node dissection in patients who undergo conservati

156 Pelvic lymph node dissection in patients with clinically locali

157 ications for omission of completion axillary lymph node dissection in patients with two or fewer node

158 The role of retroperitoneal lymph node dissection in postorchiectomy early-stage non

159 dings do not support routine use of axillary lymph node dissection in this patient population based o

160 st 20 years, and the controversy of elective lymph node dissections in this disease continues to be d

161 resent role and routine practice of axillary-lymph-node dissection in early breast cancer, the method

162 ive stage I, II, and IV disease who received lymph node dissection increased.

163 Immediate completion lymph-node dissection increased the rate of regional dis

164 Of the 59 patients, 48 had axillary lymph node dissection irrespective of the results of pat

165 Although esophagectomy with three-field lymph node dissection is commonly practiced in Japan, it

166 Complete axillary lymph node dissection is indicated in patients who prese

167 who have a positive sentinel node, axillary lymph node dissection is the present standard.

168 s, a bilateral nerve-sparing retroperitoneal lymph node dissection is the treatment of choice for pat

169 cystectomy remain undefined, and appropriate lymph node dissections laparoscopically have not been un

170 Lymph node dissection (LDN) at the time of a primary mal

171 patients did not undergo subsequent axillary lymph node dissection, leaving 95 patients for further a

172 There is good evidence that a pelvic lymph node dissection limited to the external iliac vein

173 The impact of a locoregional lymph node dissection (LND) has never been defined in th

174 To present recent advances in the field of lymph node dissection (LND) in the context of bladder ca

175 rimary lesions > 1.5 mm thick) scheduled for lymph node dissection (LND) were preoperatively studied

176 ding: What is a 'standard' versus 'extended' lymph node dissection (LND)?

177 Lateral lymph node dissection may be warranted for an upper thyr

178 This suggests that axillary lymph node dissection may not be necessary in patients w

179 Sentinel lymph node dissection may supplant standard axillary dis

180 Minimally invasive inguinal lymph node dissection (MILND) is a novel approach to ing

181 matic sampling [SS], or complete mediastinal lymph node dissection [MLND]) on DFS and OS was also stu

182 owing radical cystectomy require an extended lymph node dissection, negative surgical margins, and a

183 Black patients were less likely to undergo lymph node dissection (odds ratio [OR], 0.76 [95% CI, 0.

184 Lymph node dissection of the first basin may differ depe

185 location schedule to receive either axillary lymph node dissection or axillary radiotherapy in case o

186 ratio to SABR or lobectomy with mediastinal lymph node dissection or sampling.

187 cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling.

188 , high body mass index ( P = .039), axillary lymph node dissection ( P = .008), and more severe acute

189 osis ( P = .0404), having undergone axillary lymph node dissection ( P = .0464), and receipt of adjuv

190 body mass index >/= 25 (P = .0236), axillary lymph node dissection (P < .001), regional lymph node ir

191 Axillary lymph node dissection (P < 0.0001), higher body mass ind

192 undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for NSGCT to determine

193 s recommend postchemotherapy retroperitoneal lymph node dissection (PC-RPLND), whereas others omit su

194 40% of all postchemotherapy retroperitoneal lymph node dissections (PC-RPLND).

195 The lymph node dissection performed at the time of radical c

196 node dissection received it, and 86% of the lymph node dissections performed were necessary.

197 ction was not performed, and only 31% of the lymph node dissections performed were necessary.

198 Radical cystectomy with pelvic lymph node dissection (PLND) is the preferred treatment

199 Open radical cystectomy (ORC) and pelvic lymph node dissection (PLND) is the standard treatment f

200 rrence rate and similar survival to axillary lymph node dissection.Preoperative axillary ultrasound a

201 Although axillary lymph node dissection provides excellent regional contro

202 and included wide surgical excision, radical lymph node dissection, radiation therapy, and chemothera

203 urgical approach, particularly the extent of lymph-node dissection, radioactive iodine dosing, and th

204 imaging scenario, all patients who required lymph node dissection received it, and 86% of the lymph

205 Retroperitoneal lymph node dissection remains a prominent treatment moda

206 Radical cystectomy with bilateral pelvic lymph node dissection remains the gold standard for trea

207 Until these become widely available, pelvic lymph node dissection remains the modality of choice for

208 men who have a nerve-sparing retroperitoneal lymph node dissection (RPLND) because more patients on s

209 atients managed primarily by retroperitoneal lymph node dissection (RPLND) or chemotherapy was examin

210 CG more than 100 ng/mL, redo retroperitoneal lymph node dissection (RPLND), and second-line chemother

211 tate decision making between retroperitoneal lymph node dissection (RPLND), primary chemotherapy, and

212 diotherapy, chemotherapy, or retroperitoneal lymph node dissection (RPLND).

213 Modified template retroperitoneal lymph node dissections (RPLND) have become increasing ap

214 five had undergone previous retroperitoneal lymph node dissections (RPLNDs).

215 5 or fewer lymph node metastases, systematic lymph node dissection seems worthwhile for persistent MT

216 sy (SLNB) alone or SLNB followed by axillary lymph node dissection (SLNB/ALND) between June 1, 1999,

217 B) alone and after SLNB followed by axillary lymph node dissection (SLNB/ALND).

218 Sentinel lymph node dissection (SLND) accurately identifies nodal

219 with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axillary lymp

220 ary lymph node dissection (ALND) or sentinel lymph node dissection (SLND) alone.

221 ry dissection (TAD), which includes sentinel lymph node dissection (SLND) and selective localization

222 Sentinel lymph node dissection (SLND) has eliminated the need for

223 Marked variations in sentinel lymph node dissection (SLND) technique have been identif

224 centers, but a larger proportion of robotic lymph node dissections surpass the oncologic threshold o

225 obtain prognostic information (ie, axillary lymph node dissection), tends to minimize treatment opti

226 oted significantly more often after axillary lymph node dissection than after axillary radiotherapy a

227 ective series, randomised trials of elective lymph-node dissection, the role of 'sentinel' lymph-node

228 val times with this technique allow sentinel lymph node dissection to be performed on the same day as

229 y followed by completion level I/II axillary lymph node dissection to determine the false-negative ra

230 entinel lymph node, which will help to limit lymph node dissections to those patients with nodal meta

231 d a survival advantage for elective regional lymph node dissection, two randomized trials have not sh

232 of the tumor and suprapancreatic bile duct, lymph node dissection, vascular reconstruction, and subt

233 was 0.43% (95% CI 0.00-0.92) after axillary lymph node dissection versus 1.19% (0.31-2.08) after axi

234 n the MR imaging scenario, the necessity for lymph node dissection was based on MR imaging results an

235 ion of the fluorescent lymph nodes, a pelvic lymph node dissection was completed with robotic assista

236 e most common site of first recurrence after lymph node dissection was distant (44% of all patients).

237 In the actual scenario, one necessary lymph node dissection was not performed, and only 31% of

238 In the actual scenario, lymph node dissection was performed at the surgeon's dis

239 A complementary axillary lymph node dissection was performed in all patients to a

240 negative SLN, unless an immediate completion lymph node dissection was performed.

241 Elective lymph node dissection was the only parameter independent

242 Immediate completion lymph-node dissection was not associated with increased

243 Recurrence and survival after lymph node dissection were analyzed.

244 ion of the primary tumor and extended pelvic lymph node dissection were enrolled.

245 eated by radical prostatectomy and bilateral lymph node dissection were included in this study.

246 undergoing total mastectomy and/or axillary lymph node dissection were randomized to standard drain

247 some advocate prophylactic central cervical lymph node dissection, whereas others only rarely recomm

248 ergoes right upper lobectomy and mediastinal lymph node dissection, which demonstrate no clinical or

249 y followed by radical cystectomy with pelvic lymph node dissection, which disclosed residual high-gra

250 ed by breast-conserving surgery and axillary lymph node dissection, which revealed residual disease i

251 Establishing standards for pelvic lymph node dissection will not only increase the consist

252 A standard external iliac and obturator lymph node dissection, with or without extension to hypo

253 detectable SDM and can proceed to completion lymph node dissection without immediate CT or MRI stagin

254 ity to achieve the results of total axillary lymph node dissection without the risks of surgery or ev